What is the difference between national and provincial centralized drug collection?

The differences between national drug collection and centralized drug collection are as follows:

1, different buyers.

National procurement refers to the centralized procurement of drugs organized by the state. A number of medical institutions purchase drugs in the form of bidding through centralized bidding. The purpose of centralized bidding and purchasing drugs is to ensure the smooth implementation of the basic medical insurance system for urban workers, control the unhealthy trend in drug purchase and sale from the source, standardize the drug purchase and sale behavior of medical institutions, and reduce the burden of social medical expenses.

Centralized procurement refers to private procurement.

2. The price is different.

Through centralized bidding and purchasing of drugs, China National Mining Corporation introduced market competition mechanism to reduce the inflated drug prices. On February 3rd, 20021year, the fourth batch of centralized drug procurement organized by the state was opened in Shanghai and won the bid. Purchase products from 1 18 enterprises and 158 enterprises, and the average price of products was reduced by 52%.

The price of centralized drugs will be more expensive than that of national drugs, which is due to the lack of sales expectations of enterprises and the procurement cost is generally higher than that of national drugs.

3. There are different kinds of drugs.

The scope of centralized bidding and purchasing of drugs in China is generally the drugs used clinically in basic medical services for urban workers. Drugs that are routinely used and used in large quantities must be purchased by centralized bidding.

There are more choices of drugs collected centrally. Many drugs for rare diseases are not included in the category of national centralized collection. At this time, drugs for rare diseases will be solved through centralized collection.

The implementation effect of centralized bidding and purchasing policy for drugs

On June 23rd, 20021,the fifth batch of centralized drug procurement organized by the state was opened in Shanghai and won the bid. This centralized procurement 148 companies' 25 1 products are eligible for bidding, and the proportion of bidding products is 7 1%. In the fifth batch of centralized drug procurement organized by the state, 10 products of10 foreign pharmaceutical companies were selected for bidding, involving French Sanofi.

On June 28th, 20021,the results of the fifth batch of centralized drug procurement organized by the state were officially announced, and the drug procurement was successful on June 6th1. These drugs with reduced prices include drugs for common diseases and chronic diseases such as hypertension, coronary heart disease and diabetes, as well as drugs for major diseases such as lung cancer, breast cancer and colorectal cancer. In the fifth batch of centralized drug procurement organized by the state, the varieties of injections account for half of the total varieties of centralized drug procurement, and the amount involved accounts for about 70% of the total amount of centralized drug procurement, making it a "big family" of centralized drug procurement.

See Baidu Encyclopedia-Centralized Bidding and Purchasing of Drugs for the above contents.